Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4685-04 Phase 1 PK and safety study in healthy Japanese male adults
jRCT2071220081Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-4685 in autoimmune disease (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Safety and tolerability of ONO-4685 and Pharmacokinetics of ONO-4685. Started Jan 2023; status: completed.
02
Drugs
ONO-4685
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on jRCT2071220081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220081.